Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
GNA11 Q209L Binimetinib + Sotrastaurin uveal melanoma sensitive detail...
GNAQ Q209L Enzastaurin uveal melanoma sensitive detail...
GNAQ Q209L PD-0325901 + Sotrastaurin uveal melanoma sensitive detail...
Unknown unknown Cabozantinib uveal melanoma not applicable detail...
GNAQ Q209L Sotrastaurin uveal melanoma sensitive detail...
GNAQ Q209L NAV-2729 uveal melanoma sensitive detail...
GNAQ Q209P Sotrastaurin uveal melanoma sensitive detail...
GNAQ Q209P Enzastaurin uveal melanoma sensitive detail...
GNAQ Q209L TAK-733 uveal melanoma sensitive detail...
GNAQ Q209P TAK-733 uveal melanoma sensitive detail...
GNA11 Q209L TAK-733 uveal melanoma sensitive detail...
GNAQ Q209L Verteporfin uveal melanoma sensitive detail...
GNAQ Q209L Trametinib uveal melanoma sensitive detail...
GNA11 Q209L Trametinib uveal melanoma sensitive detail...
GNAQ Q209L GSK2126458 + Trametinib uveal melanoma sensitive detail...
GNAQ Q209L Selumetinib uveal melanoma sensitive detail...
GNAQ Q209P Selumetinib uveal melanoma sensitive detail...
GNAQ Q209L U0126 uveal melanoma sensitive detail...
GNAQ mutant CGM097 + Sotrastaurin uveal melanoma predicted - sensitive detail...
GNA11 mutant CGM097 + Sotrastaurin uveal melanoma predicted - sensitive detail...
GNAQ mutant Everolimus + Sotrastaurin uveal melanoma predicted - sensitive detail...
GNA11 mutant Everolimus + Sotrastaurin uveal melanoma predicted - sensitive detail...
GNAQ mutant Binimetinib + Sotrastaurin uveal melanoma predicted - sensitive detail...
GNA11 mutant Binimetinib + Sotrastaurin uveal melanoma predicted - sensitive detail...
Unknown unknown AU-011 uveal melanoma not applicable detail...
Unknown unknown Fotemustine + S44563 uveal melanoma not applicable detail...
Unknown unknown Pegilodecakin uveal melanoma not applicable detail...
Unknown unknown Trametinib uveal melanoma no benefit detail...
GNA11 mutant Trametinib uveal melanoma no benefit detail...
Unknown unknown Selumetinib uveal melanoma not applicable detail...
GNA11 mutant Selumetinib uveal melanoma no benefit detail...
GNAQ exon5 Selumetinib uveal melanoma no benefit detail...
GNA11 Q209L Selumetinib uveal melanoma predicted - sensitive detail...
GNAQ mutant Dacarbazine + Selumetinib uveal melanoma no benefit detail...
GNA11 mutant Dacarbazine + Selumetinib uveal melanoma no benefit detail...
Unknown unknown Ipilimumab uveal melanoma no benefit detail...
Unknown unknown Ipilimumab + Pembrolizumab uveal melanoma no benefit detail...
GNAQ Q209L FR900359 uveal melanoma sensitive detail...
GNAQ Q209P FR900359 uveal melanoma sensitive detail...
GNA11 Q209L FR900359 uveal melanoma sensitive detail...
Unknown unknown IDE196 uveal melanoma not applicable detail...
SF3B1 mutant N/A uveal melanoma not applicable detail...
Unknown unknown Sotrastaurin uveal melanoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00489944 Phase II Cisplatin + Sunitinib + Tamoxifen Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Unknown status
NCT01200238 Phase II Ganetespib STA-9090(Ganetespib) in Metastatic Ocular Melanoma Completed
NCT01430416 Phase I Sotrastaurin Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients Completed
NCT01471054 Phase II Dexamethasone intravitreal implant Bevacizumab Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma Terminated
NCT01585194 Phase II Ipilimumab Nivolumab Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma Active, not recruiting
NCT01587352 Phase II Vorinostat Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Suspended
NCT01835145 Phase II Dacarbazine Temozolomide Cabozantinib Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye Active, not recruiting
NCT01974752 Phase III Dacarbazine + Selumetinib Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed
NCT01979523 Phase II Trametinib Trametinib + Uprosertib Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma Completed
NCT02068586 Phase II Valproic acid Sunitinib Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma Recruiting
NCT02223819 Phase II Crizotinib Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy Active, not recruiting
NCT02273219 Phase I Alpelisib + Sotrastaurin Trial of AEB071 in Combination With BYL719 in Patients With Melanoma Unknown status
NCT02359851 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Advanced Uveal Melanoma Terminated
NCT02363283 Phase II Glembatumumab vedotin Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Completed
NCT02561234 Phase I Pegzilarginase A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors Completed
NCT02570308 Phase I Tebentafusp A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma Active, not recruiting
NCT02601378 Phase I HDM201 + IDE196 IDE196 A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. Active, not recruiting
NCT02768766 Phase I Selumetinib Intermittent Selumetinib for Uveal Melanoma Recruiting
NCT02913417 Phase Ib/II Ipilimumab + Nivolumab + Yttrium-90 Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases Recruiting
NCT03022565 Phase I Vorinostat Vorinostat in Patients With Class 2 High Risk Uveal Melanoma Withdrawn
NCT03052127 Phase I AU-011 Phase 1B Study in Subjects With Small to Medium Primary Choroidal Melanoma Active, not recruiting
NCT03068624 Phase I Aldesleukin + Cyclophosphamide + Ipilimumab Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma Active, not recruiting
NCT03070392 Phase II Dacarbazine Ipilimumab Pembrolizumab Tebentafusp Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma Active, not recruiting
NCT03207347 Phase II Niraparib A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Recruiting
NCT03408587 Phase I Coxsackievirus A21 + Ipilimumab CAVATAK and Ipilimumab in Uveal Melanoma Metastatic to the LIver (VLA-024 CLEVER) (CLEVER) Completed
NCT03417739 Phase II Ulixertinib A Phase II Study of BVD-523 in Metastatic Uveal Melanoma Active, not recruiting
NCT03635632 Phase I C7R-GD2.CART cells Cyclophosphamide + Fludarabine C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Recruiting
NCT03712904 Phase II Aflibercept Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma Recruiting
NCT03922880 Phase I ADI-PEG 20 + Ipilimumab + Nivolumab Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma Active, not recruiting
NCT03947385 Phase Ib/II IDE196 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Recruiting
NCT04109456 Phase I BI 853520 + Cobimetinib BI 853520 IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma Recruiting
NCT04116320 Phase I unspecified PD-1 antibody Imiquimod Imiquimod + unspecified PD-1 antibody Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (AM-003) Recruiting
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Recruiting